Dasotraline: Difference between revisions

{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc}}

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 449042592

| image = Dasotraline.svg

| width = 200

| IUPAC_name = (1''R'',4''S'')-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine

| tradename =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ATC_prefix =

| ATC_suffix =

| C=16 | H=15 | Cl=2 | N=1

| CAS_number = 675126-05-3

| CAS_number_Ref = {{cascite|correct|CAS}}

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 4D28EY0L5T

| PubChem = 9947999

| DrugBank =

| ChEMBL = 3301595

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 8123611

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D10700

| smiles = C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N

| StdInChI = 1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1

| StdInChIKey = SRPXSILJHWNFMK-MEDUHNTESA-N

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category =

| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->

| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->

| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

| legal_status =

| routes_of_administration =

'''Dasotraline''' ([[International Nonproprietary Name|INN]];<ref>{{cite journal |title=International Nonproprietary Names for Pharmaceutical Substances (INN) |journal=WHO Drug Information |volume=27 |issue=4 |year=2013 |url=https://www.who.int/medicines/publications/druginformation/PL_110.pdf |publisher=WHO |access-date=4 November 2014}}</ref> former developmental code name '''SEP-225,289''') is a [[serotonin-norepinephrine-dopamine reuptake inhibitor]] (SNDRI) that was under development by [[Sunovion]] for the treatment of [[attention-deficit hyperactivity disorder]] (ADHD) and [[binge eating disorder]] (BED).<ref name="pmid17714023">{{cite journal | vauthors = Chen Z, Skolnick P | title = Triple uptake inhibitors: therapeutic potential in depression and beyond | journal = Expert Opinion on Investigational Drugs | volume = 16 | issue = 9 | pages = 1365–77 | date = September 2007 | pmid = 17714023 | doi = 10.1517/13543784.16.9.1365 | s2cid = 20271918 }}</ref><ref name="pmid21680689">{{cite journal | vauthors = DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, Kharidia J, Robertson B, Mann JJ, Parsey RV | display-authors = 6 | title = SEP-225289 serotonin and dopamine transporter occupancy: a PET study | journal = Journal of Nuclear Medicine | volume = 52 | issue = 7 | pages = 1150–5 | date = July 2011 | pmid = 21680689 | pmc = 3856248 | doi = 10.2967/jnumed.110.084525 }}</ref><ref>{{cite journal | vauthors = Ziegler L, Küffer G, Euler E, Wilhelm K | title = [Arthrographic imaging of ganglions of the hand] | language = de | journal = RöFo | volume = 153 | issue = 2 | pages = 143–6 | date = August 1990 | pmid = 2168068 | doi = 10.1055/s-2008-1033352 | s2cid = 260312446 | trans-title = Arthrographic imaging of ganglions of the hand }}</ref><ref>{{cite journal | vauthors = Guiard B, Chenu F, El Mansari M, Blier P |title=P.1.c.059 Electrophysiological properties of the triple reuptake inhibitor SEP 225289 on monoaminergic neurons |journal=European Neuropsychopharmacology |volume=19 |year=2009 |pages=S285 |doi=10.1016/S0924-977X(09)70419-5 |s2cid=54263757 }}</ref> Structurally, dasotraline is a [[stereoisomer]] of [[desmethylsertraline]] (DMS), which is an [[active metabolite]] of the marketed [[selective serotonin reuptake inhibitor]] (SSRI) [[antidepressant]] [[sertraline]] (Zoloft).

==Adverse Effects==

In phase I clinical trials for [[ADHD|attention deficit hyperactivity disorder]], test subjects reported the following side effects:<ref>{{cite journal | vauthors = Koblan KS, Hopkins SC, Sarma K, Jin F, Goldman R, Kollins SH, Loebel A | title = Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults | journal = Neuropsychopharmacology | volume = 40 | issue = 12 | pages = 2745–52 | date = November 2015 | pmid = 25948101 | pmc = 4864650 | doi = 10.1038/npp.2015.124 }}</ref>

* [[Anorexia (symptom)|Loss of appetite]]

* [[Dehydration]]

* [[Xerostomia|Dry mouth]]

* [[Nausea]]

* [[Insomnia]]

* [[Anxiety]]

* [[Panic attacks]]

* [[Headaches]]

== History ==

In 2017, the U.S. [[Food and Drug Administration]] accepted Sunovion's [[New Drug Application]] (NDA) for review for the treatment of ADHD;<ref>{{cite press release |author=<!--Staff writer(s); no by-line.--> |title=Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD |url=http://news.sunovion.com/press-release/sunovion-announces-fda-acceptance-review-new-drug-application-dasotraline-treatment |location=Marlborough, Massachusetts |publisher=Sunovion |agency=Business Wire |date=November 10, 2017 |access-date=2018-05-01 |archive-date=2018-05-01 |archive-url=https://web.archive.org/web/20180501160846/http://news.sunovion.com/press-release/sunovion-announces-fda-acceptance-review-new-drug-application-dasotraline-treatment |url-status=dead }}</ref> however, the NDA was ultimately rejected citing the need for additional studies to determine efficacy and tolerability.<ref>{{cite web | title = FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of Adhd | url = https://news.sunovion.com/press-release/fda-issues-complete-response-letter-new-drug-application-dasotraline-treatment-adhd | publisher = Sumitomo Dainippon Pharma Co., Ltd. | date = August 31, 2018 | access-date = October 13, 2019 | archive-date = October 13, 2019 | archive-url = https://web.archive.org/web/20191013171910/https://news.sunovion.com/press-release/fda-issues-complete-response-letter-new-drug-application-dasotraline-treatment-adhd | url-status = dead }}</ref><ref>{{cite web|title=Pipeline Report: Brand Drugs|url=https://www.welldynerx.com/content/uploads/2018/02/PipelineReport-Brand-Drugs.pdf|publisher=Welldyne|access-date=1 May 2018|pages=1, 4|date=February 2018}}</ref><ref>{{ClinicalTrialsGov|NCT02276209|Dasotraline Adult ADHD Study}}</ref> In July 2019, Sunovion’s NDA for the treatment of BED was accepted with an expected action date of May 2020.<ref>{{cite web | title = Sunovion Announces Acceptance by the US FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder | url = https://news.sunovion.com/press-release/sunovion-announces-acceptance-us-fda-new-drug-application-dasotraline-treatment | publisher = Sumitomo Dainippon Pharma Co., Ltd. | date = July 30, 2019 | access-date = October 13, 2019 | archive-date = October 13, 2019 | archive-url = https://web.archive.org/web/20191013171930/https://news.sunovion.com/press-release/sunovion-announces-acceptance-us-fda-new-drug-application-dasotraline-treatment | url-status = dead }}</ref> In May 2020, Sunovion halted its drug development program for dasotraline, withdrawing both NDAs for ADHD and BED.<ref name="Sunovion dc 2020">{{cite web |title=Sunovion Discontinues Dasotraline Program |url=https://www.businesswire.com/news/home/20200513005363/en/Sunovion-Discontinues-Dasotraline-Program |website=www.businesswire.com |access-date=27 June 2020 |language=en |date=13 May 2020}}</ref>

== Law ==

=== Finland ===

Dasotraline is completely unscheduled.

== See also ==

* [[Centanafadine]]

* [[Indatraline]]

* [[Lometraline]]

* [[Tametraline]]

== References ==

{{Reflist|2}}

== Further reading ==

{{Monoamine reuptake inhibitors}}

[[Category:Serotonin–norepinephrine–dopamine reuptake inhibitors]]

[[Category:Chlorobenzene derivatives]]